Recent News

• 05.27.2026 - DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
• 05.20.2026 - DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
• 05.12.2026 - DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
• 05.06.2026 - DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
• 04.30.2026 - DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
• 03.30.2026 - DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
• 03.23.2026 - DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
• 03.05.2026 - DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
• 02.24.2026 - DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

Recent Filings

• 05.21.2026 - 8-K Current report
• 05.06.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2026 - 8-K Current report
• 05.06.2026 - EX-99.1 EX-99.1
• 04.01.2026 - DEF 14A Other definitive proxy statements
• 04.01.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.01.2026 - ARS Annual Report to Security Holders
• 03.31.2026 - EX-99.1 EX-99.1
• 03.31.2026 - 8-K Current report
• 03.30.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]